8-KEarnings & ResultsExhibits & Filings

Merck & Co., Inc. 8-K Report, Financial Results (Jul 30, 2024)

Filed July 30, 2024For Securities:MRK

Summary

Merck & Co., Inc. (MRK) filed an 8-K on July 30, 2024, to report its financial results for the second quarter of 2024. The filing incorporates by reference a press release issued on the same date, which details the company's performance. Investors should note that this information, while furnished, is not considered "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless specifically stated. The core of this report lies in the attached press release and supplemental information. These documents provide the operational and financial data for the second quarter, allowing investors to assess Merck's profitability, revenue streams, and overall financial health. Key financial metrics, strategic updates, and forward-looking guidance are typically found within these attached exhibits, making them crucial for understanding the company's current standing and future outlook.

Key Highlights

  • 1Merck & Co., Inc. filed an 8-K on July 30, 2024, reporting Q2 2024 financial results.
  • 2The report incorporates a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) for Q2 2024 earnings.
  • 3Key financial performance indicators for the second quarter are detailed in the incorporated press release and supplemental data.
  • 4The furnished information is not deemed "filed" for Section 18 purposes of the Exchange Act.
  • 5Investors should review Exhibits 99.1 and 99.2 for comprehensive Q2 2024 financial and operational details.
  • 6The filing indicates Merck's common stock and several note issuances are registered on the New York Stock Exchange.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Merck & Co., Inc.'s financial results for the second quarter of 2024. It incorporates by reference a press release and supplemental information that contain the detailed earnings data.

The detailed financial results for Q2 2024 can be found in the press release (Exhibit 99.1) and the supplemental information (Exhibit 99.2) that are incorporated by reference in this 8-K filing.

No, the information furnished in this 8-K, specifically relating to the earnings release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated by reference into other SEC filings unless explicitly stated.

Merck has its Common Stock ($0.50 par value) listed on the New York Stock Exchange, along with several series of notes due in various years (2024, 2026, 2032, 2034, 2036, 2037, 2044, and 2054).